Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.

NCT02589717 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02589717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02589717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.
Lead sponsor
Genentech, Inc.
Phase
Expanded access
Overall status
Approved for marketing
Start date
November 30, 2015
Completion date
August 31, 2016
Enrollment
Not reported
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma